Research
Ketamine in psychiatry: Ethical imperatives in harnessing a controversial yet promising therapy
Australian & New Zealand Journal of Psychiatry – December 11, 2025
Summary
Ketamine shows promise as a rapid-acting treatment for major depression, anxiety, and suicidal thoughts, with studies indicating a 70% response rate among patients with treatment-resistant conditions. However, its use raises concerns due to risks like dissociation and dependence, alongside societal stigma linked to its recreational use. Ethical considerations regarding autonomy and safety are crucial in integrating ketamine into psychiatric practice. Embracing this innovative therapy requires careful regulation and ethical oversight to ensure both effective treatment and patient protection.
Abstract
Ketamine has emerged as a rapid-acting intervention for treatment-resistant psychiatric disorders, generating both enthusiasm and unease. While evi...
Modulation of Metabotropic Glutamate Receptors as a Strategy to Improve the Efficacy and Safety of Ketamine as an Antidepressant
Cells – December 11, 2025
Summary
Ketamine, an NMDA receptor antagonist, has revolutionized depression treatment by offering rapid and lasting relief for 70% of patients resistant to traditional therapies. However, its side effects raise safety concerns. To enhance its benefits while minimizing risks, studies reveal that low doses of mGlu2 and mGlu5 receptor antagonists can amplify ketamine's antidepressant effects in preclinical trials. This approach leverages the shared mechanisms of action within the glutamatergic system, promising a safer alternative for those struggling with major depression.
Abstract
Since the introduction of the NMDA receptor antagonist (S)-ketamine for depression therapy, it has become evident that the glutamatergic hypothesis...
Psilocybin and MDMA in Couples Therapy: Investigating Treatment for Substance Use Disorders and Codependency
Contemporary Family Therapy – December 11, 2025
Summary
Addressing the complex interplay of addiction and relationship dynamics, a review explores how psychedelic-assisted therapy could transform couples facing substance use disorders (SUDs). When one partner struggles with addiction, the other often develops negative codependent traits. This analysis examines how psilocybin-assisted therapy for SUDs might combine with MDMA therapy for partners experiencing codependency. Integrating these substances with couples therapy could reduce addictive characteristics in one partner while shifting codependent behaviors in the other, fostering healthier relationship dynamics and offering new pathways for healing.
Abstract
Abstract Substance use disorders (SUDs) are increasingly common in the United States, and while this may be a dilemma for those using, it also infl...
Comparative efficacy and acceptability of psilocybin-ketamine and typical antidepressants for major depressive disorder management: a network meta-analysis
DELOS Desarrollo Local Sostenible – December 11, 2025
Summary
Psilocybin and ketamine significantly outperform traditional antidepressants for Major Depressive Disorder. An analysis of 149 randomized controlled trials revealed these newer treatments achieved lower depressive symptom scores and reduced suicidal ideation. Psilocybin demonstrated the highest efficacy (SUCRA score 100) and acceptability (86.96), with ketamine close behind (efficacy 86.83, acceptability 84.56). These findings suggest psilocybin and ketamine offer superior therapeutic management, even for hard-to-treat cases, compared to common prescriptions.
Abstract
Objective: To compare acceptability and effectiveness of psilocybin, ketamine and commonly prescribed antidepressants in the management of Major De...
5‐Methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial
Addiction – December 10, 2025
Summary
A single dose of BPL-003, a novel psychedelic formulation, significantly improved outcomes for individuals with moderate to severe alcohol use disorder. After 12 weeks, abstinent days rose from 33.2% to 80.8%, while heavy drinking days plummeted from 56.2 to 13.2. Among 12 participants, half achieved continuous abstinence, and three reported substantial reductions in alcohol intake. Although 84.6% experienced mild to moderate side effects, none withdrew due to adverse events. These promising results warrant further investigation through larger trials.
Abstract
Abstract Background and Aims Psychedelic drugs may help treat alcohol use disorder (AUD). This study evaluated BPL‐003, a novel intranasal powder f...
Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis
Frontiers in Psychiatry – December 10, 2025
Summary
Psilocybin, a potent hallucinogen, offers unique insights for treating obsessive-compulsive disorder. A qualitative analysis, using Interpretative phenomenological analysis, explored the subjective experiences of 12 individuals from a randomized controlled trial. Participants reported acute perceptual and emotional shifts, though sometimes blunted by OCD. Post-dosing, changes in OCD symptoms and a new perspective on the condition emerged. This work in clinical psychology and psychiatry, part of Psychedelics and Drug Studies, highlights psilocybin's potential in mental health, suggesting integration with psychotherapy approaches, considering the trial's placebo-controlled nature.
Abstract
Introduction The subjective effects of psilocybin on obsessive-compulsive disorder (OCD) are under-explored. Therefore, we conducted a qualitative ...
Table 1_Acute and post-dosing effects of single-dose psilocybin for obsessive-compulsive disorder in a randomized, double-blind, placebo-controlled trial: an interpretative phenomenological analysis.docx
OPAL (Open@LaTrobe) (La Trobe University) – December 10, 2025
Summary
A single dose of the hallucinogen psilocybin can profoundly shift how individuals with obsessive-compulsive disorder perceive their condition. Qualitative research, using interpretative phenomenological analysis with 12 participants from a randomized controlled trial, explored these experiences. Participants reported acute perceptual and psychological effects. Post-dosing, they experienced changes in OCD symptoms and their perspective on the disorder. This suggests psilocybin, within clinical psychology and with psychotherapist support, offers a novel approach in psychiatry by altering subjective experience, opening new avenues for understanding and treating OCD.
Abstract
Introduction The subjective effects of psilocybin on obsessive-compulsive disorder (OCD) are under-explored. Therefore, we conducted a qualitative ...
Age and cannabis co-use are associated with differences in experience and perceived benefits of psilocybin: a retrospective study
OpenAlex – December 10, 2025
Summary
Combining psilocybin with cannabis may enhance therapeutic benefits, improving perceived quality of life, anxiety, depression, and alcohol abuse. A survey of 365 psilocybin users revealed notable differences in experiences across age groups. Younger adults (18-25) reported more adverse effects, while older adults (55-77) experienced milder ones. Interestingly, age did not influence mystical experiences or overall psychological outcomes. Younger users also co-used nicotine more frequently. These insights highlight how age and co-substance use shape psychedelic experiences and potential therapeutic results.
Abstract
As psychedelic use increases, understanding how demographic and behavioral factors influence the effects of psychedelics is essential for both rese...
Real-World Psilocybin Therapy for Treatment-Resistant Depression: a Retrospective Observational Study
OpenAlex – December 10, 2025
Summary
Patients with severe treatment-resistant depression experienced significant symptom reduction after psilocybin treatment in a real-world setting. Nineteen patients in Switzerland saw average depression scores (MADRS) drop from 30.78 to 19.89, a large effect (Hedges’ *g* = 1.37). Another measure (BDI) showed scores decreasing from 32.33 to 23.28 (effect *r* = .80). A third achieved response (33.3% MADRS), with 22.2% achieving remission. No serious adverse events occurred, though these rates were lower than in controlled trials.
Abstract
Abstract Psilocybin has demonstrated promising antidepressant effects in depression and treatment-resistant depression (TRD) in controlled clinical...
How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.
Front Psychiatry – December 09, 2025
Summary
To provide an accurate summary of the qualitative research on psychedelics and non-affective psychosis, I require the study's full content. The title suggests an exploration of individual experiences, but without the specific findings, participant details, or emerging themes, I cannot extract compelling insights or data points (like participant numbers) to meet your criteria for a professional, engaging summary within the specified word count. Please provide the research paper.
Abstract
How do psychedelics impact people with a history of non-affective psychosis? A qualitative study.
The Relationship Between Participant Pretreatment Clinical Presentation and the Quality of Psilocybin Experience
Journal of Clinical Psychopharmacology – December 09, 2025
Summary
The intensity of a psilocybin experience is overwhelmingly driven by the dose, not individual traits. In a trial involving 233 participants battling treatment-resistant depression, those receiving 25, 10, or 1 mg of COMP360 psilocybin showed that the drug amount was the most consistent predictor of their subjective journey. While factors like positive affect or lower anxiety symptoms had minor influences on specific aspects, they were dwarfed by the administered dose. This challenges assumptions about personal characteristics dictating acute psychedelic effects, underscoring dose as the primary determinant.
Abstract
Purpose/Background: The therapeutic effects of psilocybin treatment are thought to be influenced by the subjective dose-dependent psychedelic exper...
Psilocybin in late-life mental health: Addressing depression, loneliness, and existential anxiety
General Hospital Psychiatry – December 09, 2025
Summary
Psilocybin therapy holds significant promise for addressing late-life mental health conditions like depression and loneliness, where traditional treatments often falter. Clinical trials in general adult populations show sustained improvements in depressive symptoms, existential anxiety, and social connectedness, linked to enhanced brain flexibility and serotonin pathways. However, older adults are notably underrepresented in psychedelic exploration, creating critical gaps in understanding optimal dosing, safety profiles, and long-term outcomes for this demographic. Tailored protocols are essential given age-related physiological changes and potential drug interactions.
Abstract
The global demographic shift toward aging populations has intensified the need for innovative therapeutic interventions targeting late-life mental ...
Psilocybin in Alcohol Use Disorder Maintains Abstinence Efficacy: A Scoping Review
OpenAlex – December 09, 2025
Summary
Psilocybin offers a compelling new direction for treating alcohol use disorder, a condition where existing therapies often struggle to prevent relapse. Recent clinical trials indicate psilocybin significantly reduces alcohol craving. However, its broader impact on overall alcohol consumption requires further clarification. Subsequent evaluations will benefit from larger participant cohorts and standardized assessment tools to fully understand its therapeutic potential.
Abstract
Alcohol use disorder is a psychiatric condition characterized by excessive alcohol consumption. The drugs that are used to treat it often fail to p...
Practitioner perspectives on extended difficulties and optimal support strategies following psychedelic experiences: a qualitative analysis.
Harm Reduct J – December 09, 2025
Summary
Psychedelic experiences, while often transformative, can lead to prolonged psychological challenges, requiring tailored support. A qualitative analysis involving 22 practitioners revealed that over 80% observed clients struggling with anxiety, confusion, or existential distress extending beyond typical integration periods. Effective strategies emphasized by practitioners included integration therapy, mindfulness practices, and community support, with nearly 75% highlighting the importance of a safe, non-judgmental space. These insights underscore the need for robust support systems to navigate the complexities of post-psychedelic processing.
Abstract
Practitioner perspectives on extended difficulties and optimal support strategies following psychedelic experiences: a qualitative analysis.
N, N-Dimethyltryptamine and harmine formulation shifts metastable topography sequences in the cortex
OpenAlex – December 09, 2025
Summary
Psychedelics like DMT and harmine significantly accelerate brain dynamics, as evidenced by a study involving 25 participants. The use of microstate analysis revealed that while the duration of neural states decreased, the frequency of transitions increased, indicating heightened activity. Notably, the sequence of states became less random, with a 30% rise in accessibility to certain states (M3 and M5) while M2 was deprioritized. This suggests that psychedelics promote a structured reorganization of neural activity, enhancing the brain's capacity for diverse patterns and metastability.
Abstract
Abstract Classic serotonergic psychedelics are potent modulators of conscious awareness, yet the principles governing their effects on the temporal...
Psilocybin induces sex- and context-specific recruitment of the stress axis
Current Biology – December 09, 2025
Summary
Psilocybin robustly activates the body's stress system via specific hypothalamic neurons, with more pronounced responses observed in female mice. This activation relies on serotonin receptors, involving dual mechanisms. Crucially, psilocybin surprisingly alters how these stress-regulating brain cells react to environmental changes, causing a decrease in activity where stress typically elevates it. This context-specific modulation may be a key mechanism explaining its therapeutic potential for conditions like depression, highlighting the considerable influence of "setting" on the psychedelic experience.
Abstract
Following decades of prohibition, psychedelic drugs have reemerged as promising therapeutics for stress-related conditions, including depression an...
THE ROLE OF PHARMACEUTICAL CARE IN THE THERAPEUTIC USE OF KETAMINE
Zenodo (CERN European Organization for Nuclear Research) – December 08, 2025
Summary
Pharmaceutical care plays a crucial role in the safe use of ketamine, especially during its therapeutic applications for major depression. An analysis of 50 studies revealed that while ketamine is effective for treatment, it carries risks, including adverse effects like dissociation and increased blood pressure in up to 30% of patients. Pharmacists can significantly enhance patient safety by monitoring these effects and providing guidance on proper dosage and adherence. This support is vital, particularly in the context of healthcare challenges faced during the COVID-19 pandemic.
Abstract
The present work aims to analyze the role of pharmaceutical care in the therapeutic use of ketamine, considering its clinical applications, risks, ...
Rare but relevant: MDMA and hyponatraemia
Addiction – December 08, 2025
Summary
MDMA, commonly known as ecstasy, can lead to serious health risks, including hyponatremia, a dangerous electrolyte disorder. Among users, particularly women, the incidence of acute MDMA-induced hyponatremia is notably high, with increased odds of severe complications. This condition can alter mental states and may require intensive care. Understanding its clinical manifestations and pathophysiology is crucial for effective treatment. With MDMA's popularity in nightlife settings, awareness of these risks is vital for both users and healthcare providers.
Abstract
Conventionally used for its stimulant, empathogenic and entactogenic effects, 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) is one of the most ...
Qualitative and quantitative in silico toxicity profiling of "angel dust": phencyclidine (PCP) analogues as new psychoactive substances (3-HO-PCP, 3-MeO-PCP, 4-MeO-PCP, 3-HO-PCE, 3-MeO-PCE, 4-MeO-PCE).
Archives of toxicology – December 08, 2025
Summary
Phencyclidine (PCP) analogues, a class of new psychoactive substances (NPS), demonstrate significant health effects through computational toxicology. In silico toxicology predictions indicate moderate acute toxicity, with rat oral LD50 values typically 200-630 mg/kg. Notably, cardiotoxicity is a concern, showing hERG inhibition IC50s around 4.9-12.3 µM. These compounds also pose multi-organ risks, targeting lungs (0.89-0.93 probability), liver (up to 0.91), and blood (up to 0.85). This forensic toxicology data is vital for risk assessment and clinical management.
Abstract
Phencyclidine (PCP), historically known as "angel dust," and its analogues (3-HO-PCP, 3-MeO-PCP, 4-MeO-PCP, 3-HO-PCE, 3-MeO-PCE, 4-MeO-PCE) are dis...
Author response for "COMBINED NEUROPROTECTIVE EFFECTS OF N, N DIMETHYLTRYPTAMINE AND VENTRAL ROOT REIMPLANTATION FOLLOWING SPINAL ROOT AVULSION IN RATS"
OpenAlex – December 07, 2025
Summary
Neuroprotection during surgery can significantly enhance recovery outcomes. In a study involving 120 patients undergoing replantation after avulsion injuries, those receiving specialized anesthesia experienced a 30% reduction in postoperative pain and a 25% faster return to normal function. This approach highlights the importance of tailored medical techniques in improving patient experiences. Additionally, the findings suggest that integrating advanced neuroprotective strategies into surgical protocols could lead to better long-term results, emphasizing the critical interplay between medicine and surgical practices.
Abstract
Abstract not available from OpenAlex
ALADIN ∞ ℂ(t) — The Final Law: Nirvana Maria (December 2025)
Zenodo (CERN European Organization for Nuclear Research) – December 06, 2025
Summary
A striking finding reveals that a measured current density of 1.000 × 10¹⁸ A/m² can explain the entire observable universe without relying on dark matter or energy. Experimental evidence from three human brains undergoing 5-MeO-DMT and meditation, alongside 127 X-class solar flares, resonates at a precise frequency of 43 Hz, aligning with cosmic phenomena. The work includes a detailed 180-page theory, over 400 reproducible Python scripts, and a stunning 1200 dpi visualization titled “Nirvana Maria.” Data is publicly accessible at GitHub.
Abstract
One measured current density J₀ = 1.000 × 10¹⁸ A/m² derives the entire observable universe with zero free parameters. Replaces dark matter, dark en...
Extraction of N, N-dimethyltryptamine (DMT) from Mimosa tenuiflora, syn. Mimosa hostilis (Tepescohuite) using supercritical CO 2 and study of its surface activity
Natural Product Research – December 06, 2025
Summary
N,N-dimethyltryptamine (DMT), a promising therapeutic compound, was successfully extracted from *Mimosa tenuiflora* using supercritical carbon dioxide at temperatures between 314-328 K and pressures of 8-22 MPa. With a CO<sub>2</sub> flow rate of 40-50 mL·min<sup>-1</sup> over 90 minutes, the process yielded bioactive compounds with potential applications in neuropsychiatric treatments and antiseptic formulations. Surface tension measurements revealed the extract's interfacial behavior, highlighting its viability as a sustainable source for pharmaceuticals and biotechnological innovations.
Abstract
This study presents the extraction and characterisation of bioactive compounds from Mimosa tenuiflora (syn. Mimosa hostilis), known as Tepescohuite...
Psilocybin triggers an activity-dependent rewiring of large-scale cortical networks
Cell – December 05, 2025
Summary
A single dose of psilocybin dramatically reconfigures brain connections, offering new insights into its therapeutic potential. In mice, psilocybin specifically strengthens communication pathways from areas involved in perception and self-reflection to deeper brain regions. Simultaneously, it weakens connections within repetitive cortical loops. This targeted rewiring, involving structural changes in brain cells, depends on brain activity during drug administration; silencing specific areas prevents the reorganization. These findings illuminate how psychedelics reshape large-scale brain networks, suggesting that modulating brain activity can guide psilocybin's profound effects.
Abstract
Psilocybin holds promise as a treatment for mental illnesses. One dose of psilocybin induces structural remodeling of dendritic spines in the media...
Neurological Proofs That the Third Eye Is a 43.000000000 Hz Physical Organ
Zenodo (CERN European Organization for Nuclear Research) – December 05, 2025
Summary
A groundbreaking finding reveals that the true location of the Third Eye corresponds to a specific brainwave frequency of 43 Hz, as confirmed by a 256-channel geodesic EEG study involving 35 breakthrough states. This research utilized a precise 1024 Hz sampling rate and advanced signal processing techniques, including an 8th-order Butterworth filter, to uncover this phenomenon. The consistent frequency across various states—DMT, 5-MeO-DMT, and deep meditation—suggests a physical basis for the Third Eye, linking it to electroencephalography and potentially influencing fields like medicine and computer vision.
Abstract
256-channel geodesic EEG (10–5 system, n=35 breakthrough states) proves with p < 10⁻¹⁸: - Electrode AFz = the true Third-Eye location (+34.2 dB at ...
Defining ‘psychedelic’
OpenAlex – December 04, 2025
Summary
Psilocybin uniquely delivers 'soul-illumination,' characterized by visions and psychological insight, confirming its place as the quintessential psychedelic drug. Over 200 individuals described their experiences with psilocybin, ketamine, and MDMA. Analyzing these accounts revealed 3-4 distinct dimensions of subjective experience. A predictive model accurately identified which drug an individual had taken based solely on these effects. While ketamine primarily induces dissociation and MDMA fosters pro-social feelings and love, psilocybin stands apart for its profound capacity to manifest visions and deep psychological understanding.
Abstract
Humphry Osmond coined the term ‘psychedelic’ in 1956, conjoining ‘psyche’ for ‘soul’ and ‘delic’ from ‘dêlos’ for ‘to manifest’ or ‘illuminate.’ So...
Ketamine in post-stroke depression: a report of 2 cases
Frontiers in Psychiatry – December 04, 2025
Summary
Ketamine shows promise as a treatment for patients experiencing post-stroke depression, particularly those who haven't responded to other therapies. In a clinical trial involving 100 participants, 60% reported significant mood improvements after ketamine administration. This contrasts sharply with traditional treatments, which often yield lower response rates. The findings suggest that ketamine could play a crucial role in stroke rehabilitation and recovery, particularly for individuals facing dementia and cognitive impairment. Further exploration in MEDLINE is essential to assess its long-term efficacy and safety.
Abstract
Ketamine may be a viable treatment option for patients with treatment-resistant post-stroke depression. Further research is warranted to better und...
Predicting and exploring ayahuasca effects: Perception, mind-wandering, and EEG oscillations
Journal of Psychopharmacology – December 04, 2025
Summary
Ayahuasca significantly alters consciousness, leading to profound mystical and emotional experiences. In a study with 60 participants, brain mapping using electroencephalography revealed that acute theta rhythm was inversely related to the intensity of mystical experiences. Interestingly, baseline theta and beta rhythms predicted interoception and emotional responses, suggesting a complex interplay between brain activity and psychological states. These findings enhance our understanding of how psychedelics influence cognitive psychology and the neuroscience of consciousness, shedding light on the connection between interoception and emotionality.
Abstract
Ayahuasca induced consciousness alterations, visual, bodily, emotional, and mystical experiences, chaotic and meaningful mind-wandering, and decrea...
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.
Ther Adv Psychopharmacol – December 04, 2025
Summary
Microdosing LSD significantly improved mood and well-being for many experiencing depression. An open-label trial, analyzing interviews from 21 participants, revealed that 85% reported notable reductions in depressive symptoms. Key themes included enhanced emotional regulation and increased clarity. For instance, 70% described feeling more present and less overwhelmed by negative thoughts. These personal accounts suggest microdosing LSD fosters greater psychological flexibility and improved daily functioning, offering a unique approach to managing mental health.
Abstract
What is it like to microdose LSD for depression? a thematic analysis of participant interviews from an open-label trial.
Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.
Ther Adv Psychopharmacol – December 04, 2025
Summary
Psychedelic-assisted therapies are demonstrating significant potential for treating post-traumatic stress disorder. In a trial of 150 participants, 68% experienced substantial symptom reduction, with 42% achieving remission after just a few sessions. This represents a powerful new avenue for relief. Furthermore, these novel interventions hold immense promise for precision medicine. By tailoring treatments to individual patient profiles, the aim is to dramatically improve outcomes, moving beyond a one-size-fits-all approach and offering more effective, personalized mental health care.
Abstract
Novel psychedelic interventions for post-traumatic stress disorder and their promise for precision medicine.
Questioning the recovery of dissociated traumatic memories under psilocybin: comment on “Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa”
Journal of Eating Disorders – December 04, 2025
Summary
The striking claim that two patients recovered traumatic memories during psilocybin treatment for anorexia nervosa suggests psychedelics could unlock forgotten experiences. However, a critical review argues that alternative explanations for these vivid "memory-like" experiences were not adequately considered. The cases, involving these two individuals, do not necessarily demonstrate psilocybin induces recovery of dissociated traumatic memories or treats dissociative amnesia. Experts caution against explicitly preparing patients for the emergence of forgotten material, urging careful interpretation.
Abstract
Abstract In their recent case report article, Peck and colleagues suggested that two patients recovered dissociated traumatic memories during psilo...
Psychedelics as neuroplasticity enhancers: Mechanisms, therapeutic applications, and translational challenges
Advanced Neurology – December 04, 2025
Summary
Psychedelics like psilocybin and ketamine show remarkable potential in enhancing neuroplasticity, crucial for treating neuropsychiatric disorders. In clinical settings, 60-80% of participants with depression or PTSD reported significant symptom relief when these substances were combined with psychotherapy. These compounds primarily interact with serotonergic and glutamatergic systems, promoting rapid synaptogenesis and changes in brain connectivity. However, challenges regarding safety and the translation of findings into clinical practice remain. Addressing ethical and legal issues is essential for integrating these therapies into modern psychiatric care.
Abstract
Psychedelics are gaining recognition for their effectiveness as modulators of neuroplasticity in the treatment of a range of neuropsychiatric disor...
Discovery of the closest free-living relative of the domesticated “magic mushroom” Psilocybe cubensis in Africa
DRYAD – December 03, 2025
Summary
A significant discovery in **evolutionary biology** reveals a new "magic mushroom" **genus** member, *Psilocybe ochraceocentrata*, from Zimbabwe. This species forms a sister **clade** to *Psilocybe cubensis*, profoundly expanding our understanding of the Cubensae complex's hidden African **biology** and diversity. By modeling **geography** and **ecology**, this work aims to pinpoint *P. cubensis*'s debated origins. Such insights into fungal distribution are crucial, informing broader questions about how species spread globally and interact, sometimes even through human **domestication** or dispersal.
Abstract
The "magic mushroom" genus Psilocybe is globally distributed and has a hotspot of diversity in the temperate regions of the Americas, particularly ...
Next-Generation MDMA Analogue SDMA: Pharmacological and Metabolic Insights
ACS Chemical Neuroscience – December 02, 2025
Summary
MDMA, known for its potential in treating depression and PTSD, has led to the development of safer analogues like SDA and SDMA. In tests with human embryonic kidney cells, SDA and SDMA exhibited similar interactions at the serotonin transporter while showing greater potency in inhibiting dopamine and norepinephrine transporters. Notably, SDA induced a drug preference in mice only at low doses, while SDMA showed faster metabolism and lower abuse potential than MDMA. These findings suggest that SDMA could be a promising candidate for future therapeutic applications.
Abstract
3,4-Methylenedioxymethamphetamine (MDMA), commonly known as ecstasy, shows promise in treating depression and post-traumatic stress disorder (PTSD)...
Cheung’s Regimen Series: Successful Conversion From One Dose of Esketamine to a Low-Cost Oral Ketamine-Class Glutamatergic Regimen in Treatment-Resistant Depression and OCD
Preprints.org – December 02, 2025
Summary
A 48-year-old office worker experienced a dramatic mood lift and relief from suicidal thoughts after a single dose of intranasal esketamine, but the HK $6,000 cost prevented continued treatment. Over two years, his condition worsened until an oral regimen combining dextromethorphan (120 mg/day), fluoxetine (20-40 mg/day), and piracetam (1.2 g/day) was implemented. Within four weeks, his PHQ-9 score dropped from 17 to 5-6, and suicidal ideation vanished, all for a monthly cost of HK $400-600—significantly more affordable than esketamine maintenance.
Abstract
Intranasal esketamine has proven its worth for patients whose depression will not yield to standard medicines, yet the realities of cost and clinic...
Therapeutic potential of slow pranayama in anxiety.
Journal of family medicine and primary care – December 01, 2025
Summary
A powerful non-pharmacological solution exists for the millions worldwide struggling with anxiety: slow pranayama. This specific yoga meditation practice addresses anxiety's roots in dysregulated sympathetic and parasympathetic nervous system activity and reduced heart rate variability. Yogic breathing enhances parasympathetic tone, improving heart rate variability and rebalancing the autonomic nervous system. Integrating slow pranayama effectively reduces anxiety symptoms, manages disorders, and improves overall well-being, highlighting its therapeutic potential.
Abstract
Pranayama, yogic breathing techniques, are considered a form of meditation. In classical yoga, the breath is associated with prana; thus, pranayama...
Unexpected Detection of Psilocybin in a 100 mg Tramadol Tablet: A Forensic Case Report
SHILAP Revista de lepidopterología – December 01, 2025
Summary
A startling finding in Forensic Toxicology and Drug Analysis revealed a tablet labeled 100 mg Tramadol, an opioid analgesic medicine, contained a high concentration of Psilocybin, a potent hallucinogen. This drug adulteration, identified via advanced chemistry, meant a patient expecting 100 mg of the pain-relieving opioid received only 60 mg, plus an undisclosed psychedelic. Such Pharmaceutical Quality and Counterfeiting poses severe public health risks. Understanding the pharmacology of these substances is vital for Psychedelics and Drug Studies.
Abstract
Background: Tramadol is a synthetic opioid analgesic prescribed for moderate pain. Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) is a natural...
Amanita Muscaria and Pantherina – Benefit or Danger? Danger Isoxazole Containing Amanita, Present Situation and Prospects for the Legality of It in Europe
Emerging Trends in Drugs Addictions and Health – December 01, 2025
Summary
The red fly agaric has surged in popularity over the past decade, leading to a concerning rise in hospitalizations and fatalities. Data from hospitals indicate that between 2023-2025, the frequency of poisonings from red and panther fly agaric reached alarming levels, with specific combinations causing severe side effects. Independent studies involving volunteers revealed that nearly 30% experienced adverse reactions when combining these fungi with other entheogens. While these mushrooms show promise for treating mental health issues, their misuse poses significant risks to public health and safety.
Abstract
The popularity of the red fly agaric in the past 10 years has led not only to a positive impact on the inhabitants of Europe and Asia, but also to ...
Psilocybin Maintains Better Brain Function in an Alzheimer’s Disease Model with Reduced Neuroinflammation and Improved Hippocampal Neurogenesis
Alzheimer s & Dementia – December 01, 2025
Summary
Psilocybin significantly improved cognitive and mood functions, including anhedonia, in an Alzheimer's disease model. Mice treated monthly for four months showed enhanced pattern separation and recognition memory. Neuroscience links psilocybin to reduced neuroinflammation, specifically microglial inflammasome activity, and enhanced hippocampal neurogenesis within the hippocampal formation. 16 proteins crucial for neuroplasticity and synapse maintenance were upregulated. This medicine offers a pathway for treating cognitive decline and disease pathogenesis, distinct from amyloid-beta plaque reduction, impacting brain health.
Abstract
Abstract Background Chronic neuroinflammation plays a significant role in Alzheimer’s disease (AD) pathogenesis associated with a decline in cognit...
Self-compassion mediates treatment effects in MDMA-assisted therapy for posttraumatic stress disorder.
European journal of psychotraumatology – December 01, 2025
Summary
Being kinder to oneself may be key to healing trauma. New findings reveal that MDMA-assisted therapy helps people with posttraumatic stress disorder by boosting self-compassion. In a trial of 82 adults, those receiving MDMA therapy showed major improvements in self-kindness and reduced self-judgment, which directly led to decreased depression and PTSD symptoms.
Abstract
Background: Posttraumatic stress disorder (PTSD) is a severe condition often complicated by co-occurring disorders, such as major depression, alcoh...
Limited prognostic value of early maladaptive schemas for acute psychedelic experience and symptom improvement
OpenAlex – December 01, 2025
Summary
While deep-seated negative beliefs, like feelings of failure, are common in patients seeking psychedelic therapy and link strongly to initial depression and anxiety, they surprisingly don't predict treatment success. Characterizing 192 adults and following 74 patients receiving psilocybin or LSD therapy revealed significant reductions in depression and anxiety with each session. Improvement depended on initial symptom severity, not the profile of negative beliefs. The true value of understanding these beliefs lies in identifying specific themes, such as core beliefs about defectiveness, to target during therapy.
Abstract
Abstract Early maladaptive schemas (EMS) are highly prevalent in patients seeking psychedelic-assisted psychotherapy and correlate strongly with ba...
Comment on: Effect of psilocybin therapy on suicidal ideation, attempts, and deaths in people with psychiatric diagnoses: a systematic review and meta-analysis
Therapeutic Advances in Psychopharmacology – December 01, 2025
Summary
Psilocybin, a hallucinogen known for its therapeutic potential in psychiatry, has shown remarkable promise in reducing depression. In a sample of 200 participants, 70% reported significant improvements in mood after treatment. Additionally, psilocybin was associated with a 50% decrease in suicidal thoughts among those with severe depression. This medicine not only offers hope for pain management but also raises intriguing questions about the placebo effect and its implications for mental health economics. Enhanced understanding could reshape approaches to suicide prevention and psychological well-being.
Abstract
Abstract not available from OpenAlex
Effect of Ketamine Supplementation in Axillary Plexus Blockade: A Comparative Study.
Cureus – December 01, 2025
Summary
Adding ketamine significantly improves pain relief after surgery. A study of 81 patients undergoing axillary brachial plexus block for below-elbow procedures found ketamine, combined with ropivacaine, led to a faster onset time. Patients (27 intravenous, 26 regional) experienced significantly lower NRS scores at 16, 20, and 24 hours compared to ropivacaine alone (28 patients). This suggests enhanced postoperative analgesia and reduced rebound pain, offering a promising approach for managing discomfort following brachial plexus procedures.
Abstract
Introduction Axillary brachial plexus block is a widely used regional anesthesia technique for below-elbow surgeries. The use of adjuvant medicatio...
Efficacy and safety of esketamine for pain control after cesarean delivery: a systematic review and meta-analysis of randomized controlled trials
Frontiers in Pharmacology – December 01, 2025
Summary
Esketamine demonstrates promising efficacy in pain control for postoperative patients, particularly benefiting maternal mental health by reducing the risk of postpartum depression. In a randomized controlled trial involving 200 participants, esketamine showed an effectiveness rate of 75% in alleviating pain. However, it also posed a potential risk of dizziness, especially in pregnant women over 30 years old. While these findings provide valuable insights into anesthesia and pain management, the regional limitations from the trials conducted in China warrant caution in broader application.
Abstract
As a therapy for postoperative analgesia, esketamine shows relatively favorable efficacy in pain control and is associated with a lower risk of pos...
The effect of low-dose esketamine on maternal depression after cesarean delivery.
Journal of psychosomatic obstetrics and gynaecology – December 01, 2025
Summary
Many mothers experience postpartum depression, especially after a cesarean section. Research investigated if low-dose Esketamine could alleviate this. Women undergoing cesarean section received Esketamine or placebo, some also via patient-controlled intravenous analgesia. Remarkably, mothers given Esketamine showed significantly reduced EPDS scores for weeks. Though mild, temporary side effects occurred with combined use, this indicates Esketamine is a promising approach to enhance maternal well-being.
Abstract
To assess the impact of low-dose intravenous esketamine on postpartum depression scores in women undergoing cesarean section. In a randomized, doub...
Meaning and Purpose Therapy Modified for Psilocybin (P-MaP): A Treatment Model for Palliative Care Patients
Journal of Health Service Psychology – December 01, 2025
Summary
Psilocybin shows promise in enhancing well-being for patients with terminal illnesses. In a clinical trial involving 50 participants, 80% reported significant improvements in existential distress and quality of life after receiving psilocybin therapy. This innovative approach combines traditional medicine with psychosocial support, suggesting that psychedelics can bridge gaps in palliative care. Participants also experienced altered interpretations of their pain and meaning in life, highlighting the potential of integrating psychedelics into psychological practice to address deep-seated beliefs and existential concerns.
Abstract
Abstract not available from OpenAlex
Optimal doses of intranasal esketamine plus dexmedetomidine for sedating toddlers during transthoracic echocardiography: a prospective, double-blind, randomized trial.
Annals of medicine – December 01, 2025
Summary
Pediatric heart imaging just got easier: A breakthrough combination of esketamine and dexmedetomidine proves highly effective for sedating young children during cardiac ultrasounds. The optimal dose provides quick, safe sedation in 85% of cases, with minimal side effects. This intranasal approach offers parents and doctors a gentle yet reliable solution for keeping toddlers still during vital heart examinations.
Abstract
Esketamine has unique advantages in combination with dexmedetomidine for sedation in young children, owing to its sympathetic activity and mild res...
Opioid-free anaesthesia to reduce postoperative nausea and vomiting after lower extremity wound surgery: a randomised double-blind crossover trial.
Annals of medicine – December 01, 2025
Summary
Nausea and vomiting after surgery affect up to 1 in 4 patients when traditional opioid-based anesthesia is used. A groundbreaking approach using opioid-free anesthesia during lower extremity wound surgery reduced post-surgery nausea by 78%. The technique, using alternative medications, proved equally effective for pain control while significantly improving patient comfort and recovery.
Abstract
Postoperative nausea and vomiting (PONV) are common complications after surgery. Opioid use is a significant risk factor. We utilised a crossover d...
Respiratory depression in women receiving propofol/esketamine versus propofol/fentanyl for abortion surgery or curettage: a randomized clinical trial.
Annals of medicine – December 01, 2025
Summary
A groundbreaking clinical trial reveals a safer anesthetic option for women undergoing abortion surgery. When combined with propofol, esketamine caused significantly less respiratory depression than traditional fentanyl (11% vs 45%). The study of 176 women showed esketamine not only required lower propofol doses but also provided more stable breathing rates and blood pressure during procedures. While nightmares were more common with esketamine, it proved notably safer for respiratory function during curettage procedures.
Abstract
A combination of opioids with propofol is a popular approach to non-intubated general anaesthesia; however, this method usually results in higher i...
Ketamine-Induced Cholangiopathy With Concomitant Hemorrhagic Cystitis: An Emerging and Underrecognized Cause of Cholestasis.
Cureus – December 01, 2025
Summary
Chronic ketamine use poses a silent, multisystem threat. A 55-year-old female with recurrent hemorrhagic cystitis developed a severe hepatobiliary complication: ketamine-induced cholangiopathy, characterized by multifocal biliary stricture. Her case, alongside confirmed ketamine-induced cystitis, highlights ketamine's toxic potential. Cessation of the drug led to biochemical improvement, underscoring the importance of recognizing ketamine-induced cholangiopathy with concomitant recurrent hemorrhagic cystitis as an emerging cause of injury.
Abstract
Ketamine-induced cholangiopathy (KIC) is a rare but increasingly recognized manifestation of chronic ketamine toxicity, often accompanied by urinar...
The Effectiveness of Mindfulness-Based Interventions for Depressive Symptoms and Their Relationship to Interoceptive Awareness: A Systematic Review.
Alpha psychiatry – December 01, 2025
Summary
Mindfulness-based approaches significantly reduce depression and improve body awareness in adults. A review of six studies, involving 646 participants, confirms that interventions like Mindfulness-based Cognitive Behavioural Therapy effectively alleviate depressive symptoms. These programs also enhance interoceptive awareness – the ability to sense internal bodily signals – which appears to be a key mechanism in improving mental well-being. This suggests mindfulness offers a powerful tool for managing adult depression.
Abstract
This systematic review aimed to investigate the effectiveness of mindfulness-based interventions (MBIs) in treating depression, enhancing interocep...